On 1st July 2017 Aurobindo Pharma Ltd (Hereafter APL) proceeded their M&A activity by merging with Generis-Farmaceutical (GFL) with value of USD 142.42 Million. The investors aim synergy-effect for their post-merger integration. A consultant firm was hired to measure their post-merger integration (PMI) results. The consultant reported their observations as follows.
1.     The R&D activity, which is the stronghold unit of GFL, has pursued the same product innovation of APL’s R&D unit.

2.     The R&D manager of APL only met GFL’s R&D manager 2 times since the merger

3.     No visitation from GFL’s R&D team to APL’s R&D unit

4.     The strategic planning of human resource management, production, and marketing program from both APL and GFL are combined

5.     The production manager of APL was given golden handshake and left the company, and now the production manager of GFL is the production manager for the newly merged company.
Based on the information above, will the synergy for the post-merger can be achieved? Analyze each dimension of the PMI’s factors.